The Trials Enabling Program (TEP)
In an Australian first, we’ve established the Trials Enabling Program (TEP) that will help people with blood cancer access promising new drugs through international clinical trials.
In 2015, the Leukaemia Foundation set out to address the lack of international clinical trial presence in Australia. We partnered with the nation’s leading blood cancer clinical trial group – the Australasian Leukaemia & Lymphoma Group (ALLG) – to establish TEP.
TEP is a mechanism that improves access of patients in Australia to the latest ground-breaking research and new therapies by bringing international clinical trials to Australia. TEP will deliver new therapeutic drugs to patients years ahead of the expected availability on the Australian market.
This innovative program is the first time an Australian charity has established a grant partnership to help patients access international blood cancer trials.
Last updated on January 30th, 2023
Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.